Description: Poolbeg Pharma PLC operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. Its products include POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, a late pre-clinical stage Melioidosis vaccine. The company also has licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma PLC was incorporated in 2021 and is headquartered in London, the United Kingdom.
Home Page: www.poolbegpharma.com
40 Bank Street
London,
E14 5NR
United Kingdom
Phone:
44 20 7183 1499
Officers
| Name | Title |
|---|---|
| Mr. Cathal Martin Friel | Executive Chairman of The Board |
| Dr. Jeremy Skillington Ph.D. | CEO & Director |
| Mr. Ian O'Connell | CFO & Director |
| Carol Dalton | Vice President of Investor Relations & Public Relations |
| Mr. John McEvoy | Senior Vice President & Chief Legal Officer |
| Mr. David James Allmond | Chief Business Officer |
| Mr. Ross Crockett | Group Financial Controller |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.7127 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 15 |